<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125971">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783574</url>
  </required_header>
  <id_info>
    <org_study_id>2012D000537</org_study_id>
    <secondary_id>R34MH09931501A1</secondary_id>
    <nct_id>NCT01783574</nct_id>
  </id_info>
  <brief_title>Testosterone Antidepressant Augmentation in Women</brief_title>
  <official_title>Collaborative Study: Testosterone Antidepressant Augmentation in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawley Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive
      symptoms in women with Major Depressive Disorder (MDD) and antidepressant
      partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women
      with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation
      improves fatigue and sexual dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>AndroFeme 1(testosterone 1% w/v cream)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, age 21-75

          2. Major depressive disorder including MADRS&gt;/=12

          3. Currently treated with an antidepressant monotherapy (1st, 2nd or 3rd trial in
             current episode), that has been taken at an adequate dose for at least six weeks.

        Exclusion Criteria:

          1. Serious suicide or homicide risk, as assessed by evaluating clinician

          2. Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurologic

          3. Substance use disorder active within last six months, or clinical suspicion of
             ongoing substance use disorder at the discretion of the study clinician at time of
             screening based on history and/or laboratory results.

          4. Any history of psychotic features, bipolar disorder, or primary obsessive compulsive
             disorder, as assessed by SCID

          5. Currently treated with typical or atypical antipsychotic medications, or lithium

          6. Untreated hypothyroidism. If treated hypothyroidism, change in levothyroxine dose
             within the prior 3 mos

          7. Use of androgens, including testosterone, dehydroepiandrosterone (DHEA) and
             methyltestosterone, within the prior three months

          8. Any investigational psychotropic drug within the last thirty days

          9. In the judgment of the study clinician, unlikely to be able to participate safely
             throughout the study period (three or more episodes of self-harm in the past year,
             documented history of poor treatment adherence, or frequent missed appointments
             (&gt;50%) in the past year)

         10. ALT &gt; 3x upper limit of normal or creatinine&gt; 3x upper limit

         11. History of a hormone-responsive cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda L Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu V Gerweck, NP</last_name>
    <phone>617-724-1837</phone>
    <email>avgerweck@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariana D Riccio, BS</last_name>
    <phone>617-726-2764</phone>
    <email>adriccio@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Gerweck, NP</last_name>
      <phone>617-724-1837</phone>
      <email>avgerweck@partners.org</email>
    </contact>
    <investigator>
      <last_name>Karen Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Fava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Carpenter, MD</last_name>
      <phone>401-455-6349</phone>
      <email>Linda_Carpenter_MD@Brown.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Carpenter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder (MDD)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
